SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is seeing increased institutional accumulation and positive sentiment driven by DefenCath market adoption and ongoing clinical developments. While shareholders are actively discussing upcoming catalyst timelines and the company's long-term commercial strategy, some investors remain focused on navigating short-term volatility and institutional positioning.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is trending as investors monitor its role in the critical AI photonics infrastructure, with community discussion focused on its $30 million CHIPS Act funding and strategic partnerships with Tower Semiconductor and Sumitomo Chemical. Traders are closely tracking the company's progress toward commercializing its non-InP semiconductor platform while weighing a significant short interest against management's recent hiring and potential future demand for high-performance optical interconnects.

Chip

Chip (USD.AI) is seeing intense community debate as market participants weigh its GPU-backed lending model against concerns regarding token supply, potential insider selling, and volatile price action. While supporters highlight the project's real-world utility in financing AI compute infrastructure, skeptics are actively shorting the asset, pointing to persistent downward pressure and the long-term dilution risks from future token unlocks.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust ETF is trending as investors grapple with significant volatility and institutional capital rotation away from digital assets amid broader concerns over liquidity and macroeconomic shifts. Market participants are actively debating the sustainability of current price support levels while monitoring how institutional positioning and potential regulatory developments continue to influence crypto market structure.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgo Bioworks is gaining attention as investors weigh its pivot toward autonomous lab infrastructure and potential alignment with U.S. national security and biosecurity policies against ongoing concerns regarding high cash burn and revenue growth. Community sentiment remains deeply polarized, with bulls tracking progress in cloud-lab partnerships and AI-driven protein engineering, while bears focus on sustained dilution risks and the company's historical failure to meet ambitious financial targets.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is gaining significant attention as investors monitor institutional accumulation and the ongoing progress of the Clarity Act, which many believe will provide essential regulatory certainty for cross-border payment utility. Community sentiment remains polarized, with some bulls emphasizing long-term institutional partnerships and tokenization potential, while skeptics point to price stagnation and the challenges of replacing traditional financial infrastructure.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is seeing intense community focus as traders track its upcoming inclusion in the Russell 2000 index, a move anticipated to drive institutional buying pressure. Meanwhile, investors are actively debating the company's long-term potential in space and defense infrastructure, with many weighing the speculative nature of its niche MRAM technology against the volatility of its recent price swings.

AirJoule Technologies Corp. operates as a thermal energy and water harvesting technology company. It provides efficient and sustainable air conditioning and pure water from air through its transformational AirJoule technology. The company was founded on March 14, 2024 and is headquartered in Ronan, MT.

AirJoule Technologies Corp. - Ordinary Shares - Class A

AirJoule Technologies is trending as investors monitor its development of atmospheric water generation systems, which are increasingly viewed as a critical solution for cooling water-intensive AI data centers. The community is actively discussing the company's potential to scale commercial operations through strategic partnerships with industrial giants like GE Vernova and Kubota, despite the firm remaining in a high-risk, pre-revenue phase.

Portillo's, Inc. operates a chain of fast-casual restaurants. Its menu includes hot dogs, Italian beef sandwiches, burgers, chicken sandwiches, salads, fries, shakes, and desserts. The company was founded in 1963 and is headquartered in Oak Brook, IL.

Portillos Inc - Ordinary Shares - Class A

Portillo's is trending as investors react to a leadership transition with the appointment of a new CEO, aiming to revitalize operational execution and growth. The community remains focused on the company's expansion strategy, foot traffic trends, and the potential for a long-term turnaround despite ongoing macro pressures.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is trending as investors weigh strong core demand against mixed performance in newer product launches like Journavx and Casgevy, while the market closely monitors progress in their high-potential kidney disease pipeline. The community remains focused on whether recent clinical updates and institutional analyst upgrades can catalyze a breakout above key technical resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus is experiencing significant market interest and high volatility following a private placement designed to fund the pivotal Phase 3 ROBBIN trial for its BOT+BAL combination therapy. The community is actively debating the impact of the financing structure, the strategic pivot toward neoadjuvant colon cancer treatment, and the influence of new institutional directors on long-term corporate governance.

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -120.00% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus...

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) delivered earnings and revenue surprises of +11.11% and +5.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Earnings Expected to Grow: Should You Buy?

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agenus to Provide Second Quarter 2026 Financial Report and Development Update

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2026 financial results before the market opens on Thursday, August 6, 2026. Agenus plans to host a webcast later in August to discuss its corporate priorities...

Do Options Traders Know Something About Agenus Stock We Don't?

Investors need to pay close attention to AGEN stock based on the movements in the options market lately.

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026...

AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot

Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.

Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Oracle, Twin Vee PowerCats, Agenus, Micron Technology and SanDisk: Why These 5 Stocks Are on Investors' Radars Today

ORCL, VEEE, AGEN, MU, SNDK were among the stocks seen trending on Monday, July 13, 2026.read more...

This account has been verified as an official AGEN representative.

Verified Account

Agenus Communications

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment

Equity

Neutral Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info